Dr. McCracken has more than twenty-five years of experience in the pharmaceutical and biotechnology industry. Until his retirement in 2013, he had a successful career in the industry where he held top managerial positions in business and commercial development and licensing at Roche Pharma, Genentech, Aventis Pharmaceuticals, and Rhone-Poulenc Rorer Pharmaceuticals. Dr. McCracken’s leadership roles at these companies included responsibility for partnering and licensing activities globally. In these positions, he oversaw the establishment of hundreds of collaborations or licensing agreements with biopharmaceutical companies and academic institutions and was part of an award-winning Business Development team at Genentech.

Since his retirement from Roche Pharma in 2013, Dr. McCracken has advised biopharmaceutical companies through Board participation and as a consultant. Dr. McCracken currently serves on the boards of two publicly listed companies, Savara Inc. (SVRA), focused on the treatment of rare respiratory diseases, and Kindred Biosciences (KIN), focused on therapeutics for animal health. In addition, Dr. McCracken is a board member for four privately held companies: Alkahest, Inc., focused on treatment for age-related conditions and diseases; Modalis Therapeutics, focused on CRISPER-based gene modulation; Neuropore Therapies, targeting neurodegenerative diseases; and Regimmune Corporation, focused on oncology, autoimmune diseases, and transplantation.

Dr. McCracken received a B.S. degree in Microbiology and Animal Science, a Doctor of Veterinary Medicine (D.V.M.), and an M.S. degree from Ohio State University.